ISSN: 1556-0864

Journal Home

Journal Guideline

Journal of Thoracic Oncology Q1 Unclaimed

Elsevier Inc. United States

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Journal of Thoracic Oncology is a journal indexed in SJR in Medicine (miscellaneous) and Oncology with an H index of 178. It has an SJR impact factor of 7,879 and it has a best quartile of Q1. It has an SJR impact factor of 7,879.

Journal of Thoracic Oncology focuses its scope in these topics and keywords: lung, cancer, patients, smallcell, cell, nsclc, treatment, chemotherapy, expression, malignant, ...

Type: Journal

Type of Copyright:

Languages:

Open Access Policy:

Type of publications:

Publication frecuency: -

Categories: Medicine (miscellaneous) (Q1) Oncology (Q1) Pulmonary and Respiratory Medicine (Q1)

Price

- €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

7,879

SJR Impact factor

178

H Index

266

Total Docs (Last Year)

803

Total Docs (3 years)

6857

Total Refs

7329

Total Cites (3 years)

395

Citable Docs (3 years)

9.53

Cites/Doc (2 years)

25.78

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Biomedical Engineering Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1
Vital and health statistics. Series 3, Analytical studies Q1

Compare this journals

Aims and Scope

Best articles by citations

Molecular Targeted Agents and Biologic Therapies for Non-small Cell Lung Cancer

P2.01-011 The Efficiency and Safety of Apatinib plus S-1 as Second-Line or Laterline Chemotherapy for Advanced Squamous Cell Lung Carcinoma

Salvage Surgery After Stereotactic Radiotherapy: A New Challenge for Thoracic Surgeons

Long-Term Active Surveillance of Screening Detected Subsolid Nodules is a Safe Strategy to Reduce Overtreatment

Optimal Lymph Node Examination and Adjuvant Chemotherapy for Stage I Lung Cancer

Multidisciplinary Management of Lung Cancer

Body Mass Index (BMI), BMI Change, and Overall Survival in Patients With SCLC and NSCLC: A Pooled Analysis of the International Lung Cancer Consortium

OA18.03 Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non-Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database

Differences in Longitudinal Health Utility between Stereotactic Body Radiation Therapy and Surgery in Stage I Non-Small Cell Lung Cancer

Program Committee

Acetylcholine Receptor Pathway and Lung Cancer

SHOW MORE ARTICLES

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience

Steering Committee

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non-Small Cell Lung Cancer

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non-Small Cell Lung Cancer (NSCLC) by State

Lungs Don't Forget: Comparison of the KRAS and EGFR Mutation Profile and Survival of Collegiate Smokers and Never Smokers with Advanced Lung Cancers

Histone Deacetylase, Proteasome, and Heat Shock Protein Inhibitors for the Treatment of Lung Cancer

Fibroblast Growth Factor Inhibitors

Impact of interleukin-22 on K-ras mutant lung cancer promotion and stemness properties

Prolonged Survival in Patients with Lung Cancer with Diabetes Mellitus

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer

Novel Taxanes/Epothilones